3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
18
Neoplasm Metastasis
14
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Recurrence
9
Ovarian Neoplasms
7
Skin Neoplasms
6
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Basal Cell
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Interventions
zenocutuzumab
2
seribantumab
2
pembrolizumab
1
patritumab
1
osimertinib
1
exemestane
1
cemiplimab
1
Vinorelbine
1
Vascular Endothelial Growth Factor A
1
Trastuzumab
1
Paroxetine
1
Paclitaxel
1
Letrozole
1
Itraconazole
1
Fulvestrant
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lethal Congenital Contracture Syndrome 2
×
cemiplimab
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled